Filed Pursuant to Rule 433 under the Securities Act of 1933

Registration Statement No. 333-285032

Issuer Free Writing Prospectus, dated November 19, 2026

 

Boston Scientific Corporation

 

$3,000,000,000

Senior Notes Offering

 

Terms and Conditions – 3-, 5-, 7- and 10-Year Fixed Rate Notes

 

  3-Year 5-Year 7-Year 10-Year
Issuer Boston Scientific Corporation
Note Type Senior Notes
Form of Offering SEC Registered
Ratings (M/S&P/F)1 A3 / A- / A- (Negative/Negative/Stable)
Principal Amount $1,000,000,000 $750,000,000 $750,000,000 $500,000,000
Trade Date November 19, 2026
Settlement Date (T+7*) December 1, 2026
Maturity Date December 1, 2029 December 1, 2031 December 1, 2033 December 1, 2036
Coupon 5.375% per annum 5.500% per annum 5.750% per annum 5.875% per annum
Yield to Maturity 5.449% per annum 5.597% per annum 5.755% per annum 5.914% per annum
Price to Public 99.798% 99.582% 99.972% 99.709%
Spread to Benchmark Treasury Plus 62 basis points Plus 72 basis points Plus 80 basis points Plus 85 basis points
Benchmark Treasury 4.625% UST due November 15, 2029 4.750% UST due October 31, 2031 4.875% UST due October 31, 2033 5.000% UST due November 15, 2036
Benchmark Treasury Yield 4.829% 4.877% 4.955% 5.064%
Benchmark Treasury Price 99-14 99-14 ¼ 99-17 99-16
Interest Payment Dates Semi-annually on June 1 and December 1 Semi-annually on June 1 and December 1 Semi-annually on June 1 and December 1 Semi-annually on June 1 and December 1
First Interest Payment Date June 1, 2027 June 1, 2027 June 1, 2027 June 1, 2027
Make-whole Call Prior to November 1, 2029, make-whole call at T+10 basis points Prior to November 1, 2031, make-whole call at T+15 basis points Prior to October 1, 2033, make-whole call at T+15 basis points Prior to September 1, 2036, make-whole call at T+15 basis points

 

 

* It is expected that delivery of the notes will be made against payment therefor on or about December 1, 2026, which will be the seventh business day following the date of pricing (such settlement cycle being referred to as “T+7”). Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to the business day before delivery will be required, by virtue of the fact that the notes initially will settle in T+7, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement and should consult their own advisors.

 

 

 

  3-Year 5-Year 7-Year 10-Year
Par Call On or after November 1, 2029 On or after November 1, 2031 On or after October 1, 2033 On or after September 1, 2036
Special Mandatory Redemption If (i) the Penumbra Acquisition is not completed on or before the Special Mandatory Redemption End Date or (ii) we notify the trustee under the indenture that we will not pursue completion of the Penumbra Acquisition, we will be required to redeem each series of the notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date.
Change of Control Repurchase Event Putable at 101% of aggregate principal amount plus accrued and unpaid interest, if any, to, but not including, the date of repurchase
Day Count Basis 30/360
Minimum Denominations $2,000 and integral multiples of $1,000 in excess of such amount
CUSIP / ISIN 101137 BB2 / US101137BB24 101137 BC0 / US101137BC07 101137 BD8 / US101137BD89 101137 BE6 / US101137BE62
Joint Bookrunners

BofA Securities, Inc.
Citigroup Global Markets Inc.
J.P. Morgan Securities LLC
Barclays Capital Inc.
Morgan Stanley & Co. LLC
Wells Fargo Securities, LLC

Co-Managers

BNP Paribas Securities Corp.
Deutsche Bank Securities Inc.
Goldman Sachs & Co. LLC
RBC Capital Markets, LLC
Scotia Capital (USA) Inc.
SG Americas Securities, LLC
Standard Chartered Bank
TD Securities (USA) LLC

Use of Proceeds We intend to use the net proceeds from this offering, together with any net proceeds of the Euro Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.
Concurrent Offering Earlier today, American Medical Systems Europe B.V., our wholly owned indirect subsidiary, priced €500.0 aggregate principal amount of its Floating Rate Notes due 2028, €500.0 aggregate principal amount of its 3.875% Senior Notes due 2028, €750.0 aggregate principal amount of its 4.125% Senior Notes due 2030, €750.0 aggregate principal amount of its 4.500% Senior Notes due 2034, €1,000.0 aggregate principal amount of its 4.750% Senior Notes due 2038 and €750.0 aggregate principal amount of its 5.125% Senior Notes due 2046 (collectively, the “Euro Notes”). The Euro Notes offering is being made by means of a separate prospectus supplement and not by means of the prospectus supplement to which this pricing term sheet relates. This communication is not an offer of any securities other than the notes to which this pricing term sheet relates. The Euro Notes offering may not be completed, and the completion of the Euro Notes offering is not a condition to the completion of the offering of the notes to which this pricing term sheet relates.

 

 

 

Note:

 

1A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

 

We have filed a registration statement (including a preliminary prospectus supplement dated November 19, 2026 (the “preliminary prospectus supplement”) and accompanying prospectus dated February 18, 2025) with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus and other documents we have filed with the SEC for more complete information about us and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, we, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus supplement and accompanying prospectus if you request it by calling BofA Securities, Inc. toll-free at 1-800-294-1322, Citigroup Global Markets Inc. toll-free at 1-800-831-9146 or J.P. Morgan Securities LLC collect at 1-212-834-4533.

 

Capitalized terms used but not defined herein have the meanings assigned to them in the preliminary prospectus supplement.

 

Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.